Home>Topics>Companies>Novo Nordisk

Novo Nordisk

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. BRIEF- Novo Nordisk says 3-year Saxenda treatment reduced diabetes risk

    Headlines

    Fri, 22 May 2015

    * Treatment with obesity drug Saxenda for three years reduced risk of developing type 2 diabetes compared with placebo

  2. UPDATE 1- Novo Nordisk , Baxter clash over haemophilia drug patent

    Headlines

    Wed, 20 May 2015

    COPENHAGEN, May 20 (Reuters) - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

  3. Novo Nordisk rejects Baxter patent claim over Novoeight

    Headlines

    Wed, 20 May 2015

    COPENHAGEN, May 20 (Reuters) - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia,...

  4. BRIEF- Novo Nordisk sells auto-immune licence to J&J unit

    Headlines

    Wed, 20 May 2015

    * Says Janssen Biotech Inc will acquire licence to further develop and commercialise a clinical programme focused on therapy within auto-immune diseases

  5. REFILE- Novo Nordisk weighs diabetes drug's use in fatty liver disease

    Headlines

    Mon, 18 May 2015

    COPENHAGEN, May 18 (Reuters) - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development.

  6. Former Novo Nordisk IT unit reports jump in profit after IPO

    Headlines

    Tue, 12 May 2015

    COPENHAGEN, May 12 (Reuters) - IT services business NNIT , a unit of drugmaker Novo Nordisk until its March listing, reported a rise in operating profit in its first earnings report as a publicly listed company on the Copenhagen stock exchange.

  7. BRIEF- Novo Nordisk says Saxenda provides benefits beyond weight loss

    Headlines

    Fri, 8 May 2015

    * Says new data demonstrated Saxenda provides benefits beyond weight loss

  8. Lundbeck's Q1 Results In-Line With Light 2015 Guidance, But New CEO Could Bring Cost Discipline

    Commentary

    Wed, 6 May 2015

    the new CEO effective mid-May buoys the outlook for the firm. Schultz brings an excellent track record as COO for Novo Nordisk , a company with exemplary operational performance and commitment to generating shareholder value. We plan to maintain

  9. UPDATE 1-Denmark's Lundbeck lands Novo Nordisk heavyweight as CEO

    Headlines

    Wed, 6 May 2015

    COPENHAGEN, May 6 (Reuters) - Drugmaker Lundbeck named Kaare Schultz as its new chief a week after the respected executive quit Novo Nordisk , a coup for the struggling smaller firm that sent its...

  10. Former Novo Nordisk executive gets top job at Denmark's Lundbeck

    Headlines

    Wed, 6 May 2015

    COPENHAGEN, May 6 (Reuters) - Danish drug company Lundbeck named Kaare Schultz as its new chief on Wednesday just a week after the respected industry executive quit Novo Nordisk when that firm's boss decided to stay on.

« Prev12345Next »
Content Partners